1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Immuneering Corporation

Immuneering Corporation

IMRX
Immuneering CorporationUS flagNASDAQ Global Market
4.28
USD
-0.21
- -
155.37MMarket Cap

Total Valuation

Immuneering Corporation carries a market capitalization of 155.37M, placing it among publicly traded companies globally. Its enterprise value stands at 117.00M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap155.37M
Enterprise Value117.00M

Share Statistics

Immuneering Corporation currently has 64.69M shares outstanding.

Shares Outstanding64.69M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

PE RatioN/A
PS RatioN/A
PB Ratio-0.92
P/TBV Ratio1.35
P/FCF Ratio-5.46
P/OCF Ratio-5.43

Financial Position

Immuneering Corporation maintains a current ratio of 32.45, meaning it holds 32.5x the short-term assets needed to cover near-term liabilities.

Current Ratio32.45
Quick Ratio31.50
Debt / Equity1.81
Debt / EBITDA-0.06
Interest CoverageN/A

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-41.01
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Stock Price Statistics

Immuneering Corporation's stock has gained approximately 118.36735% over the past 52 weeks. The 50-day moving average sits at 5.32, while the 200-day moving average is 5.82.

Beta (5Y)N/A
52-Week Price Change118.36735%
50-Day Moving Average5.32
200-Day Moving Average5.82
Average Volume (20 Days)N/A

Income Statement

EBITDA reached -58.87M, while operating income came in at -59.22M.

RevenueN/A
Gross ProfitN/A
Operating Income-59.22M
Pretax Income-54.44M
Net Income-54.44M
EBITDA-58.87M
EBIT-59.22M
Earnings Per Share (EPS)-1.06

Balance Sheet

Immuneering Corporation holds 156.69M in cash and equivalents against 3.73M in total debt, resulting in a net debt position of -47.32M. Total book value stands at -293.72M, with working capital of 156.43M providing operational flexibility.

Cash & Cash Equivalents156.69M
Total Debt3.73M
Net Debt-47.32M
Equity (Book Value)-293.72M
Book Value Per Share-5.73
Working Capital156.43M

Cash Flow

Immuneering Corporation produced -49.70M in operating cash flow over the past twelve months. After subtracting -213,211.00 in capital expenditures, free cash flow totaled -49.91M - equivalent to -0.97 per share.

Operating Cash Flow-49.70M
Capital Expenditures-213,211.00
Free Cash Flow-49.91M
FCF Per Share-0.97

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-78.88
FCF Yield-18.33

Scores

Immuneering Corporation posts an Altman Z-Score of 17.52, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score17.52